Becton Dickinson and Co
BDX209.350USD
+8.420+4.19%
Handelsschluss 04/09, 16:00(ET)Kurse um 15 Minuten verzögert
60.52BMarktkapitalisierung
35.05KGV TTM
mehr Informationen über Becton Dickinson and Co Unternehmen
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
Unternehmensinformationen
Unternehmens-codeBDX
Name des UnternehmensBecton Dickinson and Co
IPO-datumSep 25, 1963
Gegründet am1906
CEOMr. Thomas E. Polen
Anzahl der mitarbeiter74000
WertpapierartOrdinary Share
GeschäftsjahresendeSep 25
AddresseOne Becton Drive
StadtFRANKLIN LAKES
BörseNYSE Consolidated
LandUnited States of America
Postleitzahl07417-1880
Telefon12018476800
Websitehttps://www.bd.com/
Unternehmens-codeBDX
IPO-datumSep 25, 1963
Gegründet am1906
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Richard (Rick) Byrd
Mr. Richard (Rick) Byrd
Executive Vice President, President - Interventional Segment
Executive Vice President, President - Interventional Segment
754.64K
-0.32%
Mr. Timothy M. (Tim) Ring
Mr. Timothy M. (Tim) Ring
Independent Director
Independent Director
59.87K
+1.58%
Ms. Shana Carol Neal
Ms. Shana Carol Neal
Chief People Officer, Executive Vice President
Chief People Officer, Executive Vice President
47.02K
-3.86%
Ms. Catherine M. (Cathy) Burzik
Ms. Catherine M. (Cathy) Burzik
Independent Director
Independent Director
14.81K
+6.70%
Mr. Roland Goette
Mr. Roland Goette
Executive Vice President, President - EMEA
Executive Vice President, President - EMEA
14.21K
-8.25%
Mr. Antoine C. Ezell
Mr. Antoine C. Ezell
Executive Vice President, President, North America, Chief Marketing Officer
Executive Vice President, President, North America, Chief Marketing Officer
11.97K
+28.43%
Mr. Michael Feld
Mr. Michael Feld
Executive Vice President, President - Life Sciences
Executive Vice President, President - Life Sciences
9.19K
+38.45%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Director
Independent Director
9.14K
+11.33%
Ms. Michelle Quinn
Ms. Michelle Quinn
Executive Vice President, General Counsel
Executive Vice President, General Counsel
6.93K
+39.80%
Dr. Carrie L. Byington, M.D.
Dr. Carrie L. Byington, M.D.
Independent Director
Independent Director
5.25K
+21.54%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Richard (Rick) Byrd
Mr. Richard (Rick) Byrd
Executive Vice President, President - Interventional Segment
Executive Vice President, President - Interventional Segment
754.64K
-0.32%
Mr. Timothy M. (Tim) Ring
Mr. Timothy M. (Tim) Ring
Independent Director
Independent Director
59.87K
+1.58%
Ms. Shana Carol Neal
Ms. Shana Carol Neal
Chief People Officer, Executive Vice President
Chief People Officer, Executive Vice President
47.02K
-3.86%
Ms. Catherine M. (Cathy) Burzik
Ms. Catherine M. (Cathy) Burzik
Independent Director
Independent Director
14.81K
+6.70%
Mr. Roland Goette
Mr. Roland Goette
Executive Vice President, President - EMEA
Executive Vice President, President - EMEA
14.21K
-8.25%
Mr. Antoine C. Ezell
Mr. Antoine C. Ezell
Executive Vice President, President, North America, Chief Marketing Officer
Executive Vice President, President, North America, Chief Marketing Officer
11.97K
+28.43%
Umsatzaufteilung
Währung: USDUpdate-Zeit: Sun, Apr 6
Währung: USDUpdate-Zeit: Sun, Apr 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Medication Delivery Solutions
1.12B
21.75%
Medication Management Solutions
801.00M
15.50%
Integrated Diagnostic Solutions
474.00M
9.17%
Peripheral Intervention
473.00M
9.15%
Specimen Management
462.00M
8.94%
Other
1.83B
35.49%
Nach RegionUSD
Name
Umsatz
Anteil
United States
3.08B
59.58%
International
2.09B
40.42%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Medication Delivery Solutions
1.12B
21.75%
Medication Management Solutions
801.00M
15.50%
Integrated Diagnostic Solutions
474.00M
9.17%
Peripheral Intervention
473.00M
9.15%
Specimen Management
462.00M
8.94%
Other
1.83B
35.49%
Aktionäre
Update-Zeit: Fri, Feb 21
Update-Zeit: Fri, Feb 21
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
The Vanguard Group, Inc.
9.27%
BlackRock Institutional Trust Company, N.A.
5.16%
State Street Global Advisors (US)
4.91%
T. Rowe Price Investment Management, Inc.
4.22%
T. Rowe Price Associates, Inc.
4.15%
Other
72.29%
Aktionärsstatistik
Aktionäre
Anteil
The Vanguard Group, Inc.
9.27%
BlackRock Institutional Trust Company, N.A.
5.16%
State Street Global Advisors (US)
4.91%
T. Rowe Price Investment Management, Inc.
4.22%
T. Rowe Price Associates, Inc.
4.15%
Other
72.29%
Art
Aktionäre
Anteil
Investment Advisor/Hedge Fund
41.48%
Investment Advisor
41.03%
Pension Fund
2.87%
Hedge Fund
2.49%
Research Firm
2.46%
Bank and Trust
1.66%
Sovereign Wealth Fund
1.23%
Individual Investor
0.57%
Insurance Company
0.28%
Other
5.93%
Institutionelle Beteiligung
Update-Zeit: Sun, Jan 19
Update-Zeit: Sun, Jan 19
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
2806
271.64M
94.60%
-5.05M
2024Q4
2874
271.53M
94.56%
-4.62M
2024Q3
2787
266.29M
92.14%
-3.20M
2024Q2
2782
261.01M
90.31%
-2.68M
2024Q1
2797
255.99M
88.58%
-10.13M
2023Q4
2783
259.38M
89.78%
-7.79M
2023Q3
2768
264.64M
91.23%
-591.87K
2023Q2
2787
263.29M
90.78%
-570.64K
2023Q1
2795
257.22M
90.56%
-8.75M
2022Q4
2831
255.72M
90.07%
-14.76M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
26.61M
9.27%
+188.34K
+0.71%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
14.81M
5.16%
+196.28K
+1.34%
Dec 31, 2024
State Street Global Advisors (US)
14.09M
4.91%
+134.36K
+0.96%
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
12.13M
4.22%
+3.22M
+36.14%
Dec 31, 2024
T. Rowe Price Associates, Inc.
11.93M
4.15%
-1.16M
-8.84%
Dec 31, 2024
Geode Capital Management, L.L.C.
6.35M
2.21%
+66.02K
+1.05%
Dec 31, 2024
Generation Investment Management LLP
5.82M
2.03%
-139.25K
-2.34%
Dec 31, 2024
Morgan Stanley Investment Management Ltd. (UK)
5.70M
1.98%
-310.28K
-5.16%
Dec 31, 2024
MFS Investment Management
5.45M
1.9%
+708.73K
+14.93%
Dec 31, 2024
First Eagle Investment Management, L.L.C.
4.43M
1.54%
+1.06M
+31.36%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Sun, Apr 6
Update-Zeit: Sun, Apr 6
Name
Anteil
iShares U.S. Medical Devices ETF
4.18%
Natixis Vaughan Nelson Select ETF
4.12%
ClearBridge Dividend Strategy ESG ETF
3.3%
T Rowe Price Capital Appreciation Equity ETF
2.93%
First Eagle Global Equity ETF
2.82%
American Century Focused Large Cap Value ETF
2.61%
Touchstone US Large Cap Focused ETF
1.86%
ProShares MSCI Transformational Changes ETF
1.84%
T Rowe Price Equity Income ETF
1.76%
Running Oak Efficient Growth ETF
1.73%
Mehr Anzeigen
iShares U.S. Medical Devices ETF
Anteil4.18%
Natixis Vaughan Nelson Select ETF
Anteil4.12%
ClearBridge Dividend Strategy ESG ETF
Anteil3.3%
T Rowe Price Capital Appreciation Equity ETF
Anteil2.93%
First Eagle Global Equity ETF
Anteil2.82%
American Century Focused Large Cap Value ETF
Anteil2.61%
Touchstone US Large Cap Focused ETF
Anteil1.86%
ProShares MSCI Transformational Changes ETF
Anteil1.84%
T Rowe Price Equity Income ETF
Anteil1.76%
Running Oak Efficient Growth ETF
Anteil1.73%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
5.34B
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Jan 28, 2025
BDX.NB Interim Cash Dividend of gross USD 1.04 paid on Mar 31, 2025 going ex on Mar 10, 2025
Mar 10, 2025
Mar 31, 2025
Mar 10, 2025
Nov 07, 2024
BDX.NB Final Cash Dividend of gross USD 1.04 paid on Dec 31, 2024 going ex on Dec 09, 2024
Dec 09, 2024
Dec 31, 2024
Dec 09, 2024
Jul 23, 2024
BDX.NB Interim Cash Dividend of gross USD 0.95 paid on Sep 30, 2024 going ex on Sep 09, 2024
Sep 09, 2024
Sep 30, 2024
Sep 09, 2024
Apr 30, 2024
BDX.NB Interim Cash Dividend of gross USD 0.95 paid on Jun 28, 2024 going ex on Jun 10, 2024
Jun 10, 2024
Jun 28, 2024
Jun 10, 2024
Jan 23, 2024
BDX.NB Interim Cash Dividend of gross USD 0.95 paid on Mar 29, 2024 going ex on Mar 07, 2024
Mar 08, 2024
Mar 29, 2024
Mar 07, 2024
Nov 09, 2023
BDX.NB Final Cash Dividend of gross USD 0.95 paid on Dec 29, 2023 going ex on Dec 07, 2023
Dec 08, 2023
Dec 29, 2023
Dec 07, 2023
Jul 25, 2023
BDX.NB Interim Cash Dividend of gross USD 0.91 paid on Sep 29, 2023 going ex on Sep 07, 2023
Sep 08, 2023
Sep 29, 2023
Sep 07, 2023
Apr 25, 2023
BDX.NB Interim Cash Dividend of gross USD 0.91 paid on Jun 30, 2023 going ex on Jun 08, 2023
Jun 09, 2023
Jun 30, 2023
Jun 08, 2023
Jan 24, 2023
BDX.NB Interim Cash Dividend of gross USD 0.91 paid on Mar 31, 2023 going ex on Mar 09, 2023
Mar 10, 2023
Mar 31, 2023
Mar 09, 2023
Nov 10, 2022
BDX.NB Final Cash Dividend of gross USD 0.91 paid on Dec 30, 2022 going ex on Dec 08, 2022
Dec 09, 2022
Dec 30, 2022
Dec 08, 2022
Mehr Anzeigen
Aktien-Split
Datum
Art
Verhältnis

Keine Daten
Datum
Art
Verhältnis

Keine Daten